Jaguar Health crofelemer shows PS reductions in pediatric IF patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
June 30, 2026 9:01 AM EDTCompany remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases
Near-term milestones for IF program buttressed by continuing groundbreaking results of study, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare pediatric microvillus inclusion disease (MVID)
SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2026 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar") family company... More
